Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhu-pGSN in Hospitalized CAP
NCT03466073Phase 2Completed
- Sponsor
- BioAegis Therapeutics
- Start
- Aug 2018
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Recombinant human plasma gelsolin in community acquired pneumonia (CAP) (4 arms), sponsored by BioAegis Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events. Started Aug 2018; status: completed.
02
Drugs
Recombinant human plasma gelsolin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT03466073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466073.